OIntermonte Milan, January 20, 2021 Italian Research **Company Update FINE FOODS** OUTPERFORM SECTOR: Industrials Giorgio Tavolini +39-02-77115.279 Price (Eu): 10.75 e-mail: giorgio.tavolini@intermonte.it Target Price (Eu): 14.10 Andrea Randone +39-02-77115.364 e-mail: andrea.randone@intermonte.it

Entering New Adjacent Segments and Cosmetics Through Pharmatek Acquisition


- Pharmatek is now part of Fine Foods Group. Following the binding term sheet signed in mid-November, Fine Foods (FF) has finally completed the acquisition of 100% of Pharmatek PMC S.r.I. (PMC) for c. Eu17.7mn (EV). PMC is a Lombardy-based firm active in the production of biocides, cosmetics and medical devices; in FY20E PMC is supposed to have generated c. Eu17mn in revenues (Eu7mn in FY19) and c. Eu3.4mn EBITDA. Entry into other adjacent segments represents a transformational opportunity for FF, over and above the valuation multiples (PMC 5.2x vs. 8x for FF) which are somewhat influenced by last year's additional business from the production of hand sanitiser gel, which is not recurring (or at least not in the long term). We believe the PMC acquisition is still accretive even assuming a much lower recurring EBITDA (i.e. Eu2.4mn, c.70% of reported EBITDA, with profitability at 20% vs. 13-14% at FF) as it would imply a multiple of 7x EV/EBITDA'20E. Thanks to the deal, FF will enjoy doubledigit organic growth in the cosmetic segment (on top of a higher gross margin compared to solid oral forms) and cross-fertilisation opportunities from the increase in share-of-wallet related to existing clients and constant expansion of the client base thanks to the integration of the respective commercial portfolios.
- Speculative appeal from recent surge in sector M&A: The European and Italian CDMO sectors are somewhat fragmented and set for consolidation in the short to medium term, as highlighted by the recent surge in M&A activity: in particular, Procemsa's acquisition of OFI in Italy and EQT's friendly takeover bid on Swedish company Recipharm, which also has an extensive presence in Italy. We estimate FF has c.Eu100mn of M&A firepower, considering the current solid NFP (c.Eu36mn as at YE21E, including the full cashout for PMC), a mark-to-market valuation of c.Eu9mn for treasury shares (3.5% of the capital), and the possibility of increasing leverage to a comfort zone of 1.5-2x (c.Eu35-50mn), not far off the sector average.
- Change in estimates: We assume full consolidation of Pharmatek in FY21, driving FY21/22E revenues up by c.7.5%/6.4% and adj. EBITDA by 11%/9%, with the group margin improving c.0.3/0.4pp, remaining above 14% in both years. Taking into account higher D&A, this would increase 2021/22E EPS by +11%/8%.
- OUTPERFORM confirmed; target to Eu14.1 (from Eu13.0). After a temporary slowdown in 1H20 (shift in production due to Covid-19), the return to double-digit revenue growth experienced in 3Q20, in line with historical trends, supports visibility on a strong recovery in FY20, while for FY21 we expect further improvements, leveraging on Pharmatek's solid positioning in new complementary sectors (such as biocides, cosmetics and medical devices) and new forms (liquid/semiliquid). In the near future, FF is well placed to enjoy solid operating trends thanks to highly visible customer demand and the additional capacity secured through investments, as well as the ability to seize further M&A opportunities for quality assets in adjacent markets or to act as a natural aggregator domestically. Meanwhile, the potential migration to the MTA segment (and eventually the STAR) by 1H21 will be a positive future catalyst for the stock, enhancing the liquidity profile.

Key Figures	2018A	2019A	2020E	2021E	2022E
Sales (Eu mn)	139	160	177	216	237
Ebitda (Eu mn)	19	18	22	30	35
Net profit (Eu mn)	9	6	9	13	16
EPS - New Adj.(Eu)	0.370	0.352	0.431	0.562	0.674
EPS - Old Adj.(Eu)	0.370	0.352	0.431	0.507	0.625
DPS (Eu)	0.098	0.120	0.142	0.185	0.223
Ratios & Multiples	2018A	2019A	2020E	2021E	2022E
P/E Adj.	29.0	30.6	25.0	19.1	15.9
Div. Yield	0.9%	1.1%	1.3%	1.7%	2.1%
EV/Ebitda Adj.	10.6	9.8	8.7	6.9	5.5
ROCE	12.6%	6.6%	9.4%	14.1%	15.9%

oduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.

FY20 Results out March 2021 FINE FOODS - 12m Performance

Next event



RATING: Unchanged

TARGET PRICE (Eu)	: from 1	3.00 to	14.10
Ch. in Adj.EPS est:	2	020E	2021E
		0.0%	10.8%
STOCK DATA			
Reuters code:			FF.MI
Bloomberg code	:		FF IM
Performance	1m	3m	12m
Absolute	0.0%	8.1%	-12.6%
Relative	-2.3%	-7.4%	-5.7%
12 months H/L:		12	2.50/9.00
SHAREHOLDER DA	ATA		
No. of Ord. share	s (mn):		24
Total No. of share	es (mn):		24
Mkt Cap Ord (Eu	mn):		253
Total Mkt Cap (Eu	u mn):		253
Mkt Float - ord (E	u mn):		104
Mkt Float (in %):			41.0%
Main shareholde	r:		
Eigenfin Srl + M.	Eigenn	nann	51.9%
BALANCE SHEET	ATA		2021
Book value (Eu m	nn):		161
BVPS (Eu):			6.84
P/BV:			1.6
Net Financial Pos	ition (Eu	umn):	36
Enterprise value (Eu mn)	:	208

Please see important disclaimer on the last page of this report

Intermonte

Hick lyoc end 31/12/2018 31/12/2019 31/12/2020 31/12/2020 31/12/2020 PROFIT & LOSS (Eurom) Soliest 1.33 1.40 1/7 2.16 2.33 EBTA 1.9 1.8 2.2 3.0 3.1 EBTA 1.0 7 1.0 1.6 2.0 Antorces if, Deag 0.0 4 0.9 1.0 1.6 Antorces if, Deag (2) (2) 1.9 1.4 4.9 Toor cole (%) (2) (2) 1.9 1.4 4.9 Toor cole (%) (2) (2) 1.0 0.0 0.0 Microfiles, Advocatinew activities 9 8 10 1.1 1.6 2.0 0.0 Tool concernance (range) 0.307 0.259 0.37 0.562 0.644 PR statee DATA (SU) Tool concernance (range) 0.300 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	FINE FOODS - KEY FIGURES		2018A	2019A	2020E	2021E	2022E
FRIDA 19 18 22 30 35. Financial income (charges) 0 1 2 1 1 Associates & Ohese 0 0 0 0 0 0 Toxes (2) (2) (3) (4) (4) (4) Tax role (%) (6,7%) 21.4% 21.5% 22.0% 22.0% 22.0% 22.0% 20.0 0 0 Minoritis & discontinue activities 0 <t< th=""><th></th><th>Fiscal year end</th><th>31/12/2018</th><th>31/12/2019</th><th>31/12/2020</th><th>31/12/2021</th><th>31/12/2022</th></t<>		Fiscal year end	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
EBT 10 7 10 7 10 7 10 1 1 Associates & Othes 0 0 0 0 0 0 0 Perkarp profit (Los) 10 8 12 17 20 0 0 0 Davas 12 2 3 16 44 (4) </td <td>PROFIT & LOSS (Eu mn)</td> <td>Sales</td> <td>139</td> <td>160</td> <td>177</td> <td>216</td> <td>237</td>	PROFIT & LOSS (Eu mn)	Sales	139	160	177	216	237
Frienciel income (charges) 0 1 2 1 1 Associates & Ohens 0 <td></td> <td>EBITDA</td> <td></td> <td></td> <td>22</td> <td>30</td> <td>35</td>		EBITDA			22	30	35
Associates & Others 0 0 0 0 0 Pre-trap portf (Los) 10 8 12 17 20 Dors (2) (2) (3) (4) (4) Dorstofe (6) (6,7% 21.4% 21.5% 22.5% 25.5% 23.5% 33.5% <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Per-tax port (lost) 10 8 12 17 90 looks (2) (3) (4) (4) (4) looks (2) (3) (4) (4) (4) looks (2) (3) (4) (4) (4) looks (2) (3) (4) (4) looks (2) (2) (3) (3) (5) looks (4) (2) (2) (3) (3) (5) Ethic excle autorodinary lens 10 (1) (14) (4) (4) Pers state back autorodinary lens (1) (2)				•			
Taxes (2) (2) (2) (3) (4) (6) Torter [S] 16.75 21.475 21.95 22.95 Minorities & discontinue activities 0 0 0 0 0 Total actioactinory items 19 21 23 30 35 Ebit excl. setnacodinory items 19 21 23 30 35 Ebit excl. setnacodinory items 19 21 23 30 35 Ebit excl. setnacodinory items 19 8 10 13 16 Pressided 10 0.370 0.229 0.37 0.562 0.674 Evidend per store (crd) 0.078 0.120 0.142 0.185 0.223 Dividend per store (crd) 0.078 0.120 0.142 0.330% 0.330% CASH FLOW (Euron) Conse cash flow 17 18 21 26 300% Capital expenditure 132 11 1 101 101 101 101							
Tax rate (\$\$) 16.7% 21.4% 21.9% 23.9%							
Minorities of discontinue activities 0							
Net profit 9 6 9 13 16 Ebita excl. estracadinory items 19 21 23 30 35 Ebita excl. estracadinory items 10 10 11 14 20 PER SHARE DATA (Ex) Total shores out [mn] - overage td 23 23 24 24 24 Pression (Ex) Total shores out [mn] - overage td 23 23 24 24 24 Evistate Id it excl. estracadinary items 0 0.377 0.522 0.643 0.522 0.644 Evistate Id it 0.370 0.229 0.377 0.522 0.647 Evistate Id it 0.370 0.029 0.371 0.522 0.643 0.723 Dividend per share (ord) 0.078 0.120 0.142 0.185 0.33 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 0.0							
India excl. extraordinary items 0 2 1 0 0 Biblid acxl. extraordinary items 19 21 23 30 35 Biblit excl. extraordinary items 10 10 11 16 20 Net profit restruet 9 8 10 13 16 PER SHARE DATA (EQ) Total structs out (mn) - overage id 23 23 24 24 24 EPS stretated id 0.370 0.252 0.431 0.562 0.674 BVFS fd 6.360 6.322 0.442 0.885 7.324 Dividend par share (ard) 0.009 0.000 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Ebilda excl, extraordinary items 19 21 23 30 35 Het profit restated 9 8 10 113 16 PER SHARE DATA (Eq.) Total strongs out (mn) - overage (d 23 23 24 24 24 EPS restated fd 0.370 0.352 0.431 0.562 0.674 EPS restated fd 0.370 0.352 4.42 0.431 0.562 0.674 Dividend per shore (and) 0.098 0.120 0.142 0.185 0.223 Dividend per shore (and) 0.098 0.120 0.142 0.185 0.233 Dividend per shore (and) 0.090 0.000 0.000 0.000 0.000 Dividend per shore (and) 117 18 21 26 30 CASH FLOW (Eu m) Gross cash flow 17 18 21 26 30 Dividend per shore (sor) 0 0 0 0 0 0 10 Cash FLOW (Eu m) Gross cash flow							
Ebit excl. extraordinary.items 10 10 11 14 90 Net profit restated 9 8 10 13 16 PER SHARE DATA (Etc) fold shores out (mn) - overage (d 23 23 24 24 24 EPS stelded (d 0.370 0.259 0.631 0.562 0.674 Dividend per share (arc) 0.008 0.120 0.142 0.185 0.223 Dividend per share (arc) 0.008 0.000 0.010 0.00 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Net profiferatoried 9 8 10 13 16 PER SHARE DATA (EQ) Total shares out (mn) - average fd 23 23 24 24 24 EPS stated fd 0.370 0.257 0.397 0.562 0.674 BVPS fd 6.380 6.322 6.400 6.838 6.322 6.400 6.838 7.324 Dividend per shore (ard) 0.078 0.122 0.142 0.185 0.225 Dividend per shore (ard) 0.080 0.000 0.000 0.000 0.000 Dividend per shore (ard) 17 18 21 26 300 Chast RLOW (Eu mm) Grass cash flow (FCF) (33) (11) 10 12 17 Accustions, divesments & others 32 1 1 (17) 1 1 10 12 17 Accustions, divesments & others 32 1 1 (17) 1 1 10 12 17 1 1 10 12 17 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
EPS stated for 0 0.370 0.2392 0.3877 0.562 0.674 EPS restated fd 0.370 0.3370 0.5322 6.431 0.562 0.674 EPS restated fd 0.370 0.3292 6.431 0.562 0.674 Dividend per store (ord) 0.076 0.122 6.420 6.838 7.334 Dividend per store (ord) 0.076 0.000			9	8	10		16
EPS stated for 0 0.370 0.2392 0.3877 0.562 0.674 EPS restated fd 0.370 0.3370 0.5322 6.431 0.562 0.674 EPS restated fd 0.370 0.3292 6.431 0.562 0.674 Dividend per store (ord) 0.076 0.122 6.420 6.838 7.334 Dividend per store (ord) 0.076 0.000	PER SHARE DATA (Fu)		23	23	24	24	24
EPS restored fd 0.370 0.332 0.431 0.662 0.674 BVPS fd 6.360 6.322 6.400 6388 7.334 Dividend per shore (crd) 0.098 0.120 0.142 0.185 0.223 Dividend per vol trafic (%) 0.000 0.000 0.000 0.000 0.000 CASH FLOW (Euron) Cross cosh flow 17 18 21 26 30 Change in NWC (19) 2 (0) (11) (10) (11) (10) (11) Other cash flems 0 0 0 0 0 0 0 Cast FLOW (Euron) Order financing/Eury-bock 100 (12) (11) (10) (11) Order financing/Eury-bock 100 0 0 0 0 0 0 0 Cast financing // Eury-bock 100 (5) (4) 0 0 0 0 0 0 0 0 0 0 0 0 0							
Dividend per share (ord) 0.078 0.120 0.142 0.165 0.223 Dividend per share (sv) 0.000 0.000 0.000 0.000 0.000 CASH FLOW (Eu mn) Gross cash flow 17 18 21 26 30.05 CASH FLOW (Eu mn) Gross cash flow 17 18 21 26 30.05 Cash flow (Eu mn) Gross cash flow 17 18 21 26 30.05 Cash flow (Eu mn) Gross cash flow 17 18 21 26 30.05 Cash flow (FC) G33 (1) 10 12 17 Cash flow (FC) G33 (1) 0 1							
Dividend per share (sov) 0.000 0.0		BVPS fd	6.360	6.322	6.420	6.838	7.324
Dividend pay out ratio (%) 25.7% 45.0% 33.8% 33.0% 33.0% CASH FLOW (Eu mn) Gross cosh flow 17 18 21 26 30 CASH FLOW (Eu mn) Gross cosh flow (17) 18 21 26 30 Capital expenditure (32) (20) (11) (10) (11) Other cosh flow (FCF) (33) (1) 10 12 17 Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) 5 Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 7) 5 (8) 13 BALANCE SHEET (Eu mn) Total fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 Long term isobilies 0 0 107 125 123<		Dividend per share (ord)	0.098	0.120	0.142	0.185	0.223
CASH FLOW (Eu mn) Gross cash flow Change in NWC 17 18 21 26 30 Capital expenditure (32) (20) (5) (3) Optical expenditure (32) (20) (11) (10) (11) Other cash items 0 0 0 0 0 0 Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eu mn) Total fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 100 125 123 Long term liabilities 0 (2) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4)		Dividend per share (sav)	0.000	0.000	0.000	0.000	0.000
Change in NWC (19) 2 (0) (5) (3) Capital expenditure (32) (20) (11) (10) (11) Other cash items 0 0 0 0 0 Acquisitions, divestments & others 32 1 1 (17) 1 Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) Equipitation (incing/by-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Furm) Total fixed asers 83 93 92 106 101 Net capital employed 102 109 107 125 123 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0		Dividend pay out ratio (%)	25.7%	45.0%	35.8%	33.0%	33.0%
Chonge in NWC (19) 2 (0) (5) (3) Capital expenditure (32) (20) (11) (10) (11) Other cash items 0 0 0 0 0 0 Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) Equity functing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eu mn) Tool fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net working capital 21 19 19 24 27 Long term liabilities 0 0 0 0 0 Net financial position 47 40 <td>CASH FLOW (Eu mn)</td> <td>Gross cash flow</td> <td>17</td> <td>18</td> <td>21</td> <td>26</td> <td>30</td>	CASH FLOW (Eu mn)	Gross cash flow	17	18	21	26	30
Other cash items 0	. ,	Change in NWC	(19)	2	(O)	(5)	(3)
Free cash flow (FCF) (33) (1) 10 12 17 Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eumn) Total fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net financial position 47 40 45 36 50 Group equity 149 148		Capital expenditure	(32)	(20)	(11)	(10)	(11)
Acquisitions, divestments & others 32 1 1 (17) 1 Dividend 0 (2) (3) (3) (4) Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eu mn) Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net working capital 102 109 107 125 123 Net ficancial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 Adjustments (associate & minorities) 9 9 9 9 9 Net finoncial position 47 4		Other cash items	0	0	0	0	0
Dividend 0 (2) (3) (4) Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eu mn) Total fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net financial position 47 40 45 36 503 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Adjustments (associate & minorities) 9		Free cash flow (FCF)		(1)			17
Equity financing/Buy-back 100 (5) (4) 0 0 Change in Net Financial Position 67 (7) 5 (8) 113 BALANCE SHEET (Eu mn) Total fixed assets 83 93 92 106 101 Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 9 9 9 9 9 9 Net equity 134% 13.0% 13.1% 14.0% 14.8% Enterprise value 198 205							
Change in Net Financial Position 67 (7) 5 (8) 13 BALANCE SHEET (Eu mn) Total fixed assets net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) (4) Net working capital 01 102 109 107 125 123 Net financial position 47 40 45 36 50 60 0							
BALANCE SHEET (Eu mn) Total fixed assets Net working capital 10 21 19 19 92 24 106 01 Net working capital Long term liabilities 0 (2) (4) (4) (4) Net capital employed 102 109 107 125 123 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 Minorities 9							
Net working capital 21 19 19 24 27 Long term liabilities 0 (2) (4) (4) (4) Net capital employed 102 109 107 125 123 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 Adjustments (associate & minorities) 9 9 9 9 9 Net financial position 47 40 45 36 50 Enterprise value 198 205 200 208 195 RATIOS(%) EBIT Margin* 13.4% 13.0% 13.1% 14.0% EDEV/CE 2.4 1.8 1.4 1.3 1.4 1.5 Debt/Equity -31.3% -26.8% 2.4%							
Long term liabilities 0 (2) (4) (4) (4) Net capital employed 102 109 107 125 123 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 Net financial position 47 40 45 36 50 Enterprise value 198 205 200 208 195 EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm ROE* 9.2% 4.1% 6.4%	BALANCE SHEET (Eu mn)						
Net capital employed 102 109 107 125 123 Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 ENTERPRISE VALUE (Eu mn) Average mkt cap - current 253 253 253 253 253 Adjustments (associate & minorities) 9 14 14.8% 100 14.8% 16.8% 16.6% 16.1% 11.4.0%							
Net financial position 47 40 45 36 50 Group equity 149 148 151 161 173 Minorities 0 0 0 0 0 0 0 Net equity 149 148 151 161 173 ENTERPRISE VALUE (Eu mn) Average mkt cap - current 253 253 253 253 253 Adjustments (associate & minorities) 9 14 14.8 16.1 173 14.8 16.1 173 11.6 175.5 8.3% Gearing - Debt/equity <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Group equity 149 148 151 161 173 Minorities 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Minorities 0 0 0 0 0 0 Net equity 149 148 151 161 173 ENTERPRISE VALUE (Eu mn) Average mkt cap - current Adjustments (associate & minorities) 9							
Net equity 149 148 151 161 173 ENTERPRISE VALUE (Eu mm) Average mkt cap - current Adjustments (associate & minorities) 9							
ENTERPRISE VALUE (Eu mn) Average mkt cap - current Adjustments (associate & minorities) 9 14.8% 14.8% 16.6% 10.7% 10.1% 11.6 10.6 10.7% 10.2% <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Adjustments (associate & minorities) 9 9 9 9 9 9 9 Net financial position 47 40 45 36 50 Enterprise value 198 205 200 208 195 RATIOS(%) EBITDA margin* 13.4% 13.0% 13.1% 14.0% 14.8% EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm Pobt/Ebitda nm nm nm nm nm nm nm ROCE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 F							
Net financial position 47 40 45 36 50 Enterprise value 198 205 200 208 195 RATIOS(%) EBITDA margin* 13.4% 13.0% 13.1% 14.0% 14.8% EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm ROCE* 12.6% 6.6% 9.4% 14.1% 15.9% ROE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% EBITDA* 11.7% 11.3%	ENTERPRISE VALUE (Eu mn)						
Enterprise value 198 205 200 208 195 RATIOS(%) EBITDA margin* 13.4% 13.0% 13.1% 14.0% 14.8% EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm Debt/Ebitda nm nm nm nm nm nm nm ROCE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% GROWTH RATES (%) Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITA* <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
RATIOS(%) EBITDA margin* EBIT margin* 13.4% 13.0% 13.1% 14.0% 14.8% EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm Debt/Ebitda nm nm nm nm nm nm nm ROE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/CE 2.4 1.9 1.9 1.8 1.6 EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% BITDA* 11.7% 1							
EBIT margin* 7.3% 6.1% 6.3% 7.5% 8.3% Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nm nm nm nm nm Debt/Ebitda nm nm nm nm nm nm nm ROCE* 12.6% 6.6% 9.4% 14.1% 15.9% ROE* 2.4 1.9 1.9 1.8 1.6 EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% BITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4%							
Gearing - Debt/equity -31.3% -26.8% -29.5% -22.4% -28.8% Interest cover on EBIT nm nt <td>RATIOS(%)</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td></td>	RATIOS(%)	0					
Interest cover on EBIT nm nm<							
Debt/Ebitda nm nm nm nm nm nm ROCE* 12.6% 6.6% 9.4% 14.1% 15.9% ROE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% BITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%		3					
ROCE* 12.6% 6.6% 9.4% 14.1% 15.9% ROE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% BITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%							
ROE* 9.2% 4.1% 6.2% 8.4% 9.5% EV/CE 2.4 1.9 1.9 1.8 1.6 EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% GROWTH RATES (%) Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%							
EV/Sales 1.4 1.3 1.1 1.0 0.8 EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%							
EV/Ebit 19.4 21.1 17.9 12.8 9.9 Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% GROWTH RATES (%) Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%		EV/CE	2.4	1.9	1.9	1.8	1.6
Free Cash Flow Yield -13.4% -0.4% 4.1% 4.8% 6.9% GROWTH RATES (%) Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%		EV/Sales	1.4	1.3	1.1	1.0	0.8
GROWTH RATES (%) Sales 16.6% 14.6% 10.7% 22.1% 9.9% EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%		EV/Ebit	19.4	21.1	17.9	12.8	9.9
EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%		Free Cash Flow Yield	-13.4%	-0.4%	4.1%	4.8%	6.9%
EBITDA* 11.7% 11.3% 11.1% 31.2% 16.1% EBIT* 0.2% -4.7% 15.0% 45.9% 21.4% Net profit 40.3% -30.1% 53.4% 41.5% 20.0%	GROWTH RATES (%)	Sales	16.6%	14.6%	10.7%	22.1%	9.9%
Net profit 40.3% -30.1% 53.4% 41.5% 20.0%	(/•)	EBITDA*	11.7%	11.3%	11.1%	31.2%	16.1%
		EBIT*	0.2%	-4.7%	15.0%	45.9%	21.4%
EPS restated 26.9% -5.0% 22.4% 30.5% 20.0%		Net profit		-30.1%		41.5%	
		EPS restated	26.9%	-5.0%	22.4%	30.5%	20.0%

* Excluding extraordinary items

Source: Intermonte SIM estimates

Acquisition of Pharmatek

Following the binding term sheet signed in mid-November, Fine Foods (FF) has finally completed the acquisition of 100% of Pharmatek PMC S.r.l. (PMC) for c. Eu17.7mn (EV). PMC is a Lombardybased firm active in the production of biocides, cosmetics and medical devices; in FY20E PMC is supposed to have generated c. Eu17mn in revenues (Eu7mn in FY19) and c. Eu3.4mn EBITDA. Entry into other adjacent segments represents a transformational opportunity for FF, over and above the valuation multiples (PMC 5.2x vs. 8x for FF) which are somewhat influenced by last year's additional business from the production of hand sanitiser gel, which is not recurring (or at least not in the long term), but we flag that:

- FF is well placed to benefit from constant double-digit growth at organic level in the cosmetics segment;
- the multiple is quite attractive (5.2x vs. 8x for FF) and we believe the PMC acquisition would still be accretive even when assuming much lower 2020E recurring EBITDA (i.e. Eu2.4mn, c.70% of the reported figure of Eu3.4mn, with profitability at 20% vs. 13-14% at FF) as it would imply a multiple of 7x EV/EBITDA'20E.
- Fine Foods can benefit from huge cross-fertilisation synergies with PMC thanks to: 1) overlap of existing clients: FF could broaden the product range offered to existing clients, with liquid/semiliquid forms especially for dermo cosmetics and other products (e.g. Bioscalin by Giuliani for male hair treatment); 2) additional clients through the integration of the two customer portfolios.

Pharmatek (Eu mn)	2019A	2020E	2021E	2022E	2023E
Revenues	7.0	17.0	15.1	14.4	15.2
YoY growth		143%	-11%	-5%	6%
o/w recurring (estimate)	7.0	12.0	12.6	13.9	15.2
YoY growth		71%	5%	10%	10%
o/w not recurring (estimate)		5.0	2.5	0.5	0.0
EBITDA (post IFR16)	1.4	3.4	3.0	2.9	3.0
o/w recurring (estimate)	1.4	2.4	2.5	2.8	3.0
o/w not recurring (estimate)	0.0	1.0	0.5	0.1	0.0
EBITDA margin	20.0%	20.0%	20.0%	20.0%	20.0%
o/w recurring (estimate)	20.0%	20.0%	20.0%	20.0%	20.0%
o/w not recurring (estimate)		20.0%	20.0%	20.0%	20.0%
Enterprise Value		17.7			
Equity value		17.2			
net debt		0.5			
EV/EBITDA		5.2x	5.9x	6.2x	5.8x
EV/EBITDA recurring		7.4x	7.0x	6.4x	5.8x

Source: Company Data (A), Intermonte Estimates (E)

Key messages from conference call with FF management team on 16th November 2020, following the signing of the binding term sheet:

- Top line and margins: Pharmatek revenues grew from Eu7mn in FY19 (EBITDA c.Eu0.5-0.6mn but under ITA GAAP, therefore including leasing costs; we assume c.Eu1.4mn post IFRS16, hinting at a 20% margin) to Eu17mn this year (EBITDA c.Eu3.4mn). We assume c.Eu5mn in non-recurring revenues for FY20E (i.e. c.30% of the total) from the production of hand sanitiser gel.
- Customer base: Very loyal client base with a solid and long-standing relations;
- Key segments: established presence in dermo cosmetics creams (moisturising cream, skin scrubs, face cream cleansing milk), but also oral products such as mouthwash, toothpaste and a very distinctive product in the form of disinfectant tablets for dentures;
- Personnel: 60 employees (increasing from c.20 at YE19, due to higher effort on hand sanitiser gels) compared to c. 700 employees at Fine Foods.
- **Production sites:** HQ in Cremosano (Crema), relatively close (<30km) to Fine Foods headquarters in Brembate/Zingonia (Bergamo);
- CapEx: FF's management has not ruled out further possible investments to modernise production plants and machinery, as and when needed;

Intermonte

- Management: Mr. Pessah, Pharmatek's sole shareholder, has a solid background in the CDMO industry, is a very passionate manager and will stay in his role as Pharmatek General Manager for 3 years after closing (earn-out);
- **Debt:** Eu0.5m debt is a prudent preliminary indication pending confirmatory due diligence, as the company is expected to have a small positive NFP in FY20.
- Presence of retail brands: Pharmatek has some proprietary retail brands such as "pharma qui" (<u>http://www.pharmaqui.com/</u>) and "Pharma Intimo" (<u>http://www.pharmaintimo.com/</u>) and PMC (<u>http://www.pharmatek-pmc.com/prodotti.php#</u>)
- **Cash-out**: The deal foresees an all-cash payment of a maximum of Eu17.2mn for 100% of Pharmatek, split between a fixed sum of Eu11.2mn and a maximum variable payment of Eu6mn (earn-out) to be paid within the next 3 financial years.

Speculative appeal from recent surge in Sector M&A

There was a significant resurgence in M&A activity in the Italian CDMO sector in December:

- Procemsa, an Italian CDMO owned by Investistindustrial, announced the acquisition of Officina Farmaceutica Italiana (OFI), a Bergamo-based CDMO, located close to Fine Foods and active in nutraceuticals as well as pharma, with turnover of c. Eu20m in FY19 and 68 employees. Procemsa's headquartered are at Nichelino in Turin province, and the company employs 115 people. Thanks to this acquisition, group turnover will reach Eu50mn (vs. c. Eu180mn for Fine Foods in FY20E). The group will concentrate on expansion in markets with high growth potential, especially the USA, China and Asia.
- Swedish fund EQT has launched a friendly takeover bid on Recipharm, also from Sweden, for \$2.1bn, a + 23% premium to the last closing price pre-bid. Recipharm is a pharma segment CDMO, with over Eu1.1bn in turnover of which over 80% from CMDO for pharma clients. Italy is Recipharm's second largest market, in which it generated revenues of c. Eu190mn in FY19 (similar in size to Fine Foods), accounting for 17.8% of consolidated turnover (just below Sweden at 18.2%). At current prices (SEK225.6, slightly above the SEK220 bid), Recipharm is trading at 16/14x '20/21E EV/EBITDA (Fine Foods 9/7x) vs. 13/11x pre-bid. The takeover has Recipharm management's consent (management has 25.7% of the share capital and 74.3% of voting rights) and the EQT offer was immediately accepted. The offer is conditional on obtaining 90% of the share capital with the aim of de-listing the stock. Faced with higher investments to satisfy client demand and sector consolidation opportunities taking place through M&A, both EQT and Recipharm management are convinced the Group could benefit from operating as a private firm in the years to come. In November 2019, Recipharm bought Consort Medical for c.Eu620mn in cash (c. SEK 6.3bn), an EV /EBITDA multiple of 13.3x, taking over 9 Consort plants in the UK, Italy and Germany.

Our view: The European and Italian CDMO sectors are somewhat fragmented and set for consolidation in the short-medium term. Fine Foods is well placed to take advantage of its twin presence in the nutraceutical sector (75% of Group revenues: Fine Foods is the largest European CDMO in the food supplements sector while Recipharm does not participate in the nutraceutical segment) and in pharma; from this year it will be able to access the attractive cosmetics segment thanks to finalisation of the acquisition of Pharmatek. We estimate M&A firepower for Fine Foods of c.Eu100mn, considering the current solid NFP (c.Eu36mn as at YE21E, including the full cashout for Pharmatek), a mark-to-market valuation of c.Eu9mn for its treasury shares (3.5% of the share capital), and the possibility of increasing leverage to a comfort zone of 1.5-2x (c.Eu35-50mn), not far off the sector average.

Change in Estimates

We assume full consolidation of Pharmatek in FY21, driving FY21/22E revenues up by c.7.5%/6.4% and adj. EBITDA by 11%/9%, with the group margin improving c.0.3/0.4pp, remaining above 14% in both years. Taking into account higher D&A, this would **increase 2021/22E EPS by +11%/8%**.

			New Es	timates			Old Es	timates					
(Eu mn)	'19A	'20E	'21E	'22E	'23E	'20E	'21E	'22E	'23E	'20E	'21E	'22E	'23E
Food	119.2	133.5	153.5	172.0	185.7	133.5	153.5	172.0	185.7				
Pharma	40.5	43.3	47.2	51.0	53.1	43.3	47.2	51.0	53.1				
Pharmatek	0.0	0.0	15.1	14.4	15.2	0.0	0.0	0.0	0.0				
Revenues	159.7	176.8	215.9	237.3	254.0	176.8	200.8	223.0	238.8	0.0%	7.5%	6.4%	6.4%
YoY growth	14.6%	10.7%	22.1%	9.9%	7.0%	10.7%	13.5%	11.1%	7.1%				
Adj. EBITDA	20.8	23.1	30.3	35.2	38.9	23.1	27.3	32.3	35.8	0.0%	11.1%	8.9 %	8.5%
Adj. EBITDA Margin	13.0%	13.1%	14.0%	14.8%	15.3%	13.1%	13.6%	14.5%	15.0%				
Adj. EBIT	9.7	11.2	16.3	19.8	22.4	11.2	14.7	18.3	20.8	0.0%	11.2%	8.2%	7.6%
Adj. EBIT Margin	6.1%	6.3%	7.5%	8.3%	8.8%	6.3%	7.3%	8.2%	8.7%				
Net Profit	6.1	9.3	13.2	15.8	17.6	9.3	11.9	14.7	16.4	0.0%	10.8%	7.9%	7.4%
Adj. Net profit	8.2	10.1	13.2	15.8	17.6	10.1	11.9	14.7	16.4	0.0%	10.8%	7.9%	7.4%
Adj. EPS (€/share)	0.35	0.43	0.56	0.67	0.75	0.43	0.51	0.62	0.70	0.0%	10.8%	7.9%	7.4%
Op. FCF	2.4	12.1	15.7	21.8	25.3	12.1	11.2	19.0	22.7	0.0%	40.1%	14.5%	11. 3 %
as % of Adj. EBITDA	11%	52%	52%	62%	65%	52%	41%	59%	63%				
Equity FCF	(0.9)	10.1	11.6	16.8	19.6	10.1	7.5	14.4	17.3	0.0%	55.6%	16. 9 %	1 2.7%
Net Cash (Debt)	39.8	44.6	36.2	49.6	65.0	44.6	49.7	61.2	74.7				
Net Cash/Adj. EBITDA	1.9x	1.9x	1.2x	1.4x	1.7x	1.9x	1.8x	1.9x	2.1x				

Source: Company Data (A), Intermonte Estimates (E)

New Estimates 2020-23 (including Pharmatek)

Fine Foods – Income Statement

(Eu mn)	2015A	2016A	2017A	2018A	2019A	2020E	2021E	2022E	2023E
Total Revenues	102.0	113.1	119.6	139.4	159.7	176.8	215.9	237.3	254.0
Total Operating Costs	(88.7)	(98.0)	(104.1)	(120.7)	(141.7)	(154.7)	(185.5)	(202.1)	(215.1)
EBITDA	13.3	15.1	15.5	18.7	18.0	22.1	30.3	35.2	38.9
% EBITDA Margin	13%	13%	13%	13%	11%	13%	14%	15%	15%
Depr. Prov's. and Write-down	(5.2)	(5.8)	(6.6)	(8.5)	(11.1)	(11.9)	(14.0)	(15.4)	(16.5)
EBIT	8.1	9.3	9.0	10.2	6.9	10.2	16.3	19.8	22.4
% EBIT Margin	7.9%	8.2%	7.5%	7.3%	4.3%	5.7%	7.5%	8.3%	8.8%
Net Financial Charges	(0.3)	(0.2)	(0.4)	0.2	0.8	1.7	0.5	0.5	0.5
Other Charges and Income	-	-	-	-	-	-	-	-	-
Net Operating Margin	7.8	9.0	8.5	10.4	7.7	11.9	16.8	20.3	22.9
Taxes	(3)	(3)	(2)	(2)	(2)	(3)	(4)	(4)	(5)
Tax Rate %	-32%	-31%	-27%	-17%	-21%	-22%	-22%	-22%	-23%
Net Income	5.3	6.2	6.2	8.7	6.1	9.3	13.2	15.8	17.6

Source: Company data (A) and Intermonte SIM estimates (E)

Fine Foods – Balance Sheet									
(Eu mn)	2015A	2016A	2017A	2018A	2019A	2020E	2021E	2022E	2023E
Fixed assets:									
- Intangible	2.2	1.9	1.7	4.5	3.6	3.4	3.4	3.4	3.4
- Tangible	38.9	41.6	57.3	78.6	89.3	88.8	102.2	97.4	92.4
- Financial	-	-	-	-	-	-	-	-	-
Total Fixed Assets	40.3	42.9	58.6	82.9	92.8	92.3	105.6	100.9	95.8
Net working capital	10.3	10.3	2.0	20.6	19.0	19.3	24.2	27.0	29.1
Gross inv. capital	50.7	53.2	60.6	103.5	111.8	111.6	129.9	127.9	124.9
Severance provision	(0.0)	(0.0)	-	-	(2.3)	(3.9)	(3.8)	(3.8)	(3.8)
Net invested capital	49.3	51.9	59.4	102.5	108.5	106.7	125.0	123.0	120.1
Group sharehold. equity	31.5	32.7	38.9	149.2	148.3	151.4	161.2	172.7	185.1
Minority interests	-	-	-	-	-	-	-	-	-
Net Debt /(Net Cash)	17.8	19.3	20.4	(46.7)	(39.8)	(44.6)	(36.2)	(49.6)	(65.0)
Total cover	49.3	51.9	59.3	102.5	108.5	106.7	125.0	123.0	120.1

Source: Company data (A) and Intermonte SIM estimates (E)

(Eu mn)	2015A	2016A	2017A	2018A	2019A	2020E	2021E	2022E	2023E
Net fin position beg of year	(14.3)	(17.8)	(19.3)	(20.4)	46.7	39.8	44.6	36.2	49.6
Net income	5.3	6.2	6.2	8.7	8.2	10.1	13.2	15.8	17.6
Depreciation	5.2	5.8	6.6	8.5	11.1	11.9	14.0	15.4	16.5
Change in working capital	(6.5)	0.0	8.3	(18.6)	1.7	(0.4)	(4.9)	(2.7)	(2.1)
Others	0.0	-	-	0.3	(1.8)	(1.0)	(1.0)	(1.0)	(1.0)
FCF before capex	4.0	12.1	21.1	(1.1)	19.2	20.7	21.3	27.5	31.0
Investments	(7.5)	(10.0)	(21.9)	(31.7)	(20.1)	(10.6)	(9.7)	(10.7)	(11.4)
Equity FCF	(3.5)	2.1	(0.8)	(32.8)	(0.9)	10.1	11.6	16.8	19.6
Acquisitions	-	-	-	-	-	-	(17.7)	-	-
Disposals	-	-	0.0	0.0	1.0	1.0	1.0	1.0	1.0
Dividends	-	(5.0)	-	-	(2.2)	(2.7)	(3.3)	(4.4)	(5.2)
Share Buy-back	-	-	-	-	(4.7)	(3.5)	-	-	-
Rights Issue/ ipo	-	-	-	100.0	-	-	-	-	-
Other	7.4	11.5	21.5	31.6	-	-	-	-	-
Cash flow	3.9	8.6	20.7	98.8	(6.8)	4.8	(8.4)	13.5	15.3
Net fin position end of year	(17.8)	(19.3)	(20.4)	46.7	39.8	44.6	36.2	49.6	65.0

Source: Company data (A) and Intermonte SIM estimates (E)

(Eu mn)	2015A	2016A	2017A	2018A	2019A	2020E	2021E	2022E	2023E
EBITDA adjusted	13.3	15.1	16.7	18.7	20.8	23.1	30.3	35.2	38.9
Capex	(7.5)	(10.0)	(21.9)	(31.7)	(20.1)	(10.6)	(9.7)	(10.7)	(11.4)
Delta WKC	(6.5)	0.0	8.3	(18.6)	1.7	(0.4)	(4.9)	(2.7)	(2.1)
Op.FCF	(0.7)	5.1	3.1	(31.6)	2.4	12.1	15.7	21.8	25.3
as % of Adj. EBITDA	n.m.	34%	19%	n.m.	11%	52%	52%	62%	65%
Interest&Taxes	(2.8)	(3.1)	(4.0)	(1.5)	(1.5)	(1.1)	(3.1)	(4.0)	(4.8)
Other	-	-	-	0.3	(1.8)	(1.0)	(1.0)	(1.0)	(1.0)
Equity FCF	(3.5)	2.1	(0.8)	(32.8)	(0.9)	10.1	11.6	16.8	19.6

Source: Company data (A) and Intermonte SIM estimates (E)

Fine Foods: Enhancing Reputation on ESG Themes

Fine Foods was subject to an ESG audit by Nummus.info S.p.A., a company operating in the monitoring of investment portfolios from the point of view of sustainability and active as a research centre for ethical and sustainable finance, as well as a member of the Forum for Sustainable Finance and subscriber to the United Nations Principles for Responsible Investment (UN PRI).

Nummus auditors went to Fine Foods's Zingonia-Verdellino plant in person, attended a company presentation based mainly on aspects of sustainability and ethics, and were provided with a guided tour of the entire production chain.

Based on the publicly available information on the Nummus.info website, the information obtained during the meeting with top management and on the basis of the visit to the production site, Nummus.info S.p.A rated Fine Foods & Pharmaceuticals NTM S.p.A. an ESG LEADER, the highest possible ranking.

Fine Foods – ESG leading ranking according to Nummus.info

ESG LAGGARD

Source: Nummus.info, Fine Foods

Nummus.Info

Valuation

We use a DCF approach to value Fine Foods, restricting the comparison with peers' multiples to a mere sanity check, given the lack of significance of the peer group due to very high diversification in terms of size, level of vertical integration, geographical footprint, capital structure, and profitability.

DCF Valuation

We assume the following parameters in our DCF valuation:

- WACC at 7.3% (previously: 7.5%), which reflects a 2.0% risk-free rate (previously: 2.5%);
- Terminal growth rate of 1.5% (unchanged);
- Long-term EBITDA margin of 14.5% (previously: 14.0%),
- CapEx/sales ratio at c.4.5% (unchanged), in line with usual level of maintenance CapEx.

This yields an increased target price of Eu14.1 (from Eu13), which already reflects the share count of 24.5mn adjusted for warrant and special share conversion. At our TP, the stock would trade at 9.9x/8.1x EV/EBITDA 2021E/'22E (current prices: 6.9x/5.5x), still at a discount compared to the overall sector, but broadly in line with current Labomar multiples (9.2x/8.0x).

Fine Foods – DCF Model

(Eumn)	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	τν
Net Revenues	176.8	215.9	237.3	254.0	268.9	281.7	293.0	302.8	310.7	316.7	322.4	327.1
YoY growth	10.7%	22.1%	9.9%	7.0%	5.9%	4.7%	4.0%	3.3%	2.6%	1.9%	1.8%	1.5%
EBITDA	23.1	30.3	35.2	38.9	40.9	42.5	44.0	45.1	46.0	46.6	47.1	47.3
% margin	13.1%	14.0%	14.8%	15.3%	15.2%	15.1%	15.0%	14.9%	14.8%	14.7%	14.6%	14.5%
D&A	(12.9)	(14.0)	(15.4)	(16.5)	(16.9)	(17.3)	(17.5)	(17.7)	(17.9)	(18.1)	(18.3)	(14.7)
ЕВП	10.2	16.3	19.8	22.4	24.0	25.2	26.4	27.4	28.1	28.4	28.8	32.5
% margin	5.7%	7.5%	8.3%	8.8%	8.9%	9.0%	9.0%	9.1%	9.0%	9.0%	8.9%	10.0%
Taxes	(2.4)	(3.9)	(4.7)	(5.4)	(5.8)	(6.1)	(6.3)	(6.6)	(6.7)	(6.8)	(6.9)	(7.8)
taxrate	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%	-24.0%
Change in WC	(0.4)	(4.9)	(2.7)	(2.1)	(4.0)	(4.0)	(4.0)	(4.0)	(4.0)	(4.0)	(4.0)	(2.2)
Capex	(10.6)	(9.7)	(10.7)	(11.4)	(12.1)	(12.7)	(13.2)	(13.6)	(14.0)	(14.3)	(14.5)	(14.7)
Unlevered FCF	9.7	11.8	17.0	19.9	19.0	19.8	20.4	20.9	21.3	21.5	21.7	22.5
TV												385.2
year	0.0	1.0	2.0	3.0	4.0	5.0	6.0	7.0	8.0	9.0	10.0	11.0
Discounted WACC	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5
Discounted Free cash flow	9.7	11.0	14.8	16.1	14.4	13.9	13.4	12.8	12.1	11.4	10.7	177.5

Discounted FCF '21E-30E	130.6
Terminal v alue	177.5
Total EV (with DCF)	308.0
NFP/(Debt) at YE20E	44.6
Acquisitions	(17.7)
Minorities	0.0
Treasury shares	8.9
Total EQUITY (Eu mn)	343.9
No. of shares fully diluted (mn)	24.5
Fair value (Eu/share)	14.1
current price (Eu/share)	10.75
upside/downside vs current price	30.7%

Source: Company Data (A), Intermonte estimates (E)

							g					
		1.0%	1.1%	1. 2 %	1.3%	1.4%	1.5%	1.6%	1.7%	1. 8 %	1. 9 %	2.0%
	6.3%	14.7	14.8	15.0	15.2	15.4	15.6	15.7	15.9	16.2	16.4	16.6
	6.5%	14.4	14.6	14.7	14.9	15.0	15.2	15.4	15.6	15.8	16.0	16.2
	6.7%	14.1	14.3	14.4	14.6	14.7	14.9	15.1	15.2	15.4	15.6	15.8
	6.9 %	13.9	14.0	14.2	14.3	14.4	14.6	14.7	14.9	15.1	15.2	15.4
U U	7.1%	13.7	13.8	13.9	14.0	14.2	14.3	14.5	14.6	14.8	14.9	15.1
WACC	7.3%	13.4	13.6	13.7	13.8	13.9	14.1	14.2	14.3	14.5	14.6	14.8
≥	7.5%	13.2	13.4	13.5	13.6	13.7	13.8	13.9	14.1	14.2	14.3	14.5
	7.7%	13.1	13.2	13.3	13.4	13.5	13.6	13.7	13.8	14.0	14.1	14.2
	7.9%	12.9	13.0	13.1	13.2	13.3	13.4	13.5	13.6	13.7	13.8	14.0
	8 .1%	12.7	12.8	12.9	13.0	13.1	13.2	13.3	13.4	13.5	13.6	13.7
	8.3%	12.5	12.6	12.7	12.8	12.9	13.0	13.1	13.2	13.3	13.4	13.5

Fine Foods – TP Sensitivity to WACC (%) and g (%)

Source: Intermonte SIM estimates (E)

Peer Multiples

The reference table on the last page of this report provides a comparison with some players in the CDMO sector and/or in healthcare product manufacturing. Given the limited relevance of the peer group due to high diversification in terms of size, level of vertical integration, geographical footprint, capital structure and profitability when compared to Fine Foods, we do not take the peers multiples method into account in our valuation. At current prices, Fine Foods trades at 6.9x/5.5x EV/adj. EBITDA'21/'22, at a discount of c.55/60% to the peer group.

Fine Foods - Peer Multiples

Company	Currency	Price	Mkt. Cap	Ab	s. Perf.	(%)	EV	//Sales	(x)	EV/	EBITDA	(x)	E	V/EBIT	(x)	A	dj. P/E ((x)	Div	. Yield	(%)
company	contency	ince	(Eu mn)	1m	6m	Ytd	2020E	2021E	2022E	2020E	2021E	2022E	2020E	2021E	2022E	2020E	2021E	2022E	2020E	2021E	2022E
Fine Foods	EUR	10.8	253	-3.2%	-1.4%	-10.4%	1.1	1.0	0.8	8.6	6.9	5.5	17.9	12.8	9.9	25.1	19.2	16.0	1.3%	1.7%	2 .1%
FF @TP (Outperf.)	EUR	14.1	344				1.6	1.4	1.2	12.6	9.9	8.1	26.0	18.3	14.4	34.1	26.1	21.7	1.0%	1.3%	1.6%
Catalent	USD	116.90	15,863	11.3%	49.4%	87.1%	6.9	5.7	5.1	28.6	23.0	20.0	38.6	30.4	26.8	55.0	41.6	35.9	0.0%	0.0%	0.0%
Labomar SpA	EUR	7.19	133	-4.7%	0.0%	0.0%	2.2	2.0	1.7	11.4	9.2	8.0	17.6	13.9	12.2	22.2	19.9	17.3	1.3%	1.5%	1.7%
PharmaNutra S.p.A.	EUR	38.10	369	18.3%	61.3%	2.9%	6.0	5.4	4.9	22.3	22.7	19.2	25.8	25.5	21.4	34.5	35.1	30.2	1.3%	1.4%	1.5%
Recipharm AB Class B	SEK	225.60	2,251	43.5%	88.8%	66.6%	2.8	2.6	2.4	16.2	13.8	12.2	37.8	27.3	22.6	49.1	32.7	26.2	0.7%	0.9%	1.1%
Siegfried Holding AG	CHF	629.50	2,542	-1.2%	45.9%	34.4%	3.7	3.0	2.7	22.0	17.1	14.7	35.1	26.0	21.6	41.7	31.8	27.0	0.5%	0.5%	0.6%
Strides Pharma	INR	907.25	916	18.3%	101.5%	135.9%	2.8	2.4	2.0	13.5	10.8	8.9	19.4	15.1	12.1	26.1	18.4	14.0	0.7%	0.6%	0.7%
Peer Group							3.3	2.8	2.6	19.1	15.4	13.4	30.5	25.7	21.5	38.1	32.3	26.6	0.7%	0.7%	0.9%

Source: Intermonte Estimates (E), Factset Consensus



CAGR

CAGR

·10-[,]18


3.7%

Other




Appendix

Focus on Key Reference Markets



🖗 The European Nutraceuticals market has shown high, steady growth, and is expected to accelerate in coming years

Source: company presentation



France 5.6% 2.4 (40%) (19%) 2.0 1.1 (18% Germany 6.6% (22%) 1.2 (20%) 2.1 (23%) Italy 6.2% 1.3 (22%) 2010 2018 CDMO CAGR 5.2% VS PHARMA CAGR 3.5% between 2010

in coming years. CDMO-driven development and manufacturing,

9.0

3.2

(36%)

and 2018: Plenty of space for CDMOs to grow further along the outsourcing trend

Italy is confirmed at first place in Europe with a market share of 23%

Source: company presentation

Source: company presentation

EU Pharmaceutical CDMO Market Value – € bn

5.29

mostly outsourced


6.0

Source: company presentation

10

Fine Foods – Benchmarking Analysis ITALY

- Fine Foods is the largest Italian CDMO
- Fine Foods is one of the few players active in both Pharmaceuticals and Nutraceuticals
 - $^{
 m O}$ Fine Foods revenues increased 12.6% more than average competitors growth



SELECTED FINE FOODS' COMPETITORS AT ITALIAN LEVEL – 2019 and 2018 REVENUES (€M)

Note: Nutrilinea, Doppel, Biopharma, Nutrilinea, Mipharm, Procemsa and OFI are controlled by Private Equity Investor Source: Management elaboration on publicly retrievable selected information

Source: Company presentation


Fine Foods – Benchmarking Analysis EUROPE

Fine Foods' goal is to achieve premium European positioning, leveraging (i) its business mix and solid business model, and (ii) a strong financial position enabling inorganic growth

In general, the largest European CDMOs are focused almost exclusively on Pharmaceuticals

Fine Foods revenues increased 8.5% more than average competitors growth





Source: Company presentation



Appendix

Peer Group Description

Catalent Catalent, Inc. is a holding company that engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and provides manufacturing services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and provides manufacturing services for blow-fillseal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses on formulation, development and manufacturing technologies and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets, and conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labelling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered at Somerset, NJ.

Labomar Labomar is a CDMO active in Food Supplements, Medical Devices, Food markets for Special Medical Purposes, Functional Cosmetics and Non-Functional Cosmetics, falling within the broader sector of nutraceuticals. Labomar stands out for being an advanced and researchdriven CDMO, as in addition to the activities that typically connote a CDMO, it is able to offer its customers control of the entire value chain (full service), starting upstream with complex internal research activities, able to propose proprietary formulas and technologies with a proactive approach to the market. Furthermore, Labomar in its own judgment guarantees high quality products and high added value. Following completion of the ImportFab Transaction, the Issuer, through the Canadian subsidiary ImportFab - CMO (Contract Manufacturing Organization), active in the production and packaging of liquid forms and semi-solid products for the pharmaceutical industry, the cosmetic industry and the nutraceutical industry - has expanded its offer portfolio and the reference geographical market. On a residual basis, the Group also provides consultancy services in R&D area and regulatory consultancy services in the United States of America and Canada through ImportFab. The Labomar Group supplies its products to companies in the pharmaceutical, nutraceutical, cosmetic and medical devices.

- Recipharm Recipharm AB engages in the manufacturing of pharmaceuticals and in contract development services for pharmaceutical companies. It operates in the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies, and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment makes products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and has its headquarters in Stockholm, Sweden.
- Siegfried Holding Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programmes, related intermediates, and controlled substances. It also provides development and production services for finished dosage forms including sterile filling. The company was founded by Samuel Benoni Siegfried in 1873 and is based in Zofingen, Switzerland.

Strides PharmaStrides Pharma Science Ltd. engages in the development, manufacture and distribution ofScienceInternet Protocol-led generics and bio-pharmaceutical products. The company was founded
by Arun N. Kumar on June 28, 1990 and has its headquarters in Bangalore, India.

FINE FOODS Peer Group - Absolute Performances

Stock	Price	Ccy	Mkt cap	1M	3M	6M	YTD	1Y	2Y
FINE FOODS	10.75	EUR	253	0.0%	8.1%	-3.2%	2.4%	-12.6%	12.0%
BOIRON	36.70	EUR	643	-8.6%	-12.6%	8.4%	-11.2%	7.0%	-28.5%
CATALENT	115.50	USD	19,023	10.0%	25.0%	35.3%	11.0%	89.7%	224.3%
CLOVER CORP.	1.44	AUD	239	-7.1%	-28.7%	-35.7%	-13.5%	-46.1%	3.6%
DERMAPHARM	59.70	EUR	3,214	7.2%	37.2%	26.1%	4.8%	59.1%	159.5%
ICON	210.35	USD	11,101	8.3%	3.2%	11.5%	7.9%	19.7%	57.9%
JUBILANT LIFE SCIENCES	975.65	INR	155,403	26.2%	41.3%	43.7%	15.5%	71.6%	37.8%
LABORATORIOS FARM. R	43.30	EUR	2,399	11.9%	36.6%	35.3%	14.2%	69.1%	140.6%
LANXESS	63.86	EUR	5,514	2.0%	26.6%	33.0%	1.8%	13.3%	31.1%
PROBI	468.00	SEK	5,332	11.2%	33.7%	42.0%	10.9%	105.7%	27.5%
RECIPHARM	222.00	SEK	22,389	1.9%	42.7%	64.9%	1.2%	74.0%	114.4%
SIEGFRIED	618.00	CHF	2,566	-1.4%	-2.8%	35.6%	-5.1%	29.7%	67.9%
STRIDES PHARMA SCIEN	908.45	INR	81,429	16.7%	22.1%	112.7%	3.5%	134.9%	75.9%
Mean performance				6.0%	17. 9 %	31.5%	3.3%	47.3%	71.1%
Italy FTSE Mib	22,381.4	EUR		1.8%	15.4%	9.6%	0.7%	-7.3%	13.6%

Source: FactSet

FINE FOODS Peer Group - Multiple Comparison

Stock	Price	Ccy	Mkt cap	EV/Sales 2021	EV/Sales 2022	EV/Ebitda 2021	EV/Ebitda 2022	EV/Ebit 2021	EV/Ebit 2022	P/E 2021	P/E 2022	Div Yield 2021	Div Yield 2022	_
FINE FOODS	10.75	EUR	253	1.0	0.8	6.9	5.5	12.8	9.9	19.1	15.9	1.7%	2.1%	
BOIRON	36.70	EUR	643	0.8	0.8	4.0	3.5	6.4	5.2	17.5	14.8	2.4%	3.3%	Ξ
CATALENT	115.50	USD	19,023	5.6	5.1	22.7	19.8	30.6	26.4	44.9	38.5	0.0%	0.0%	T
CLOVER CORP.	1.44	AUD	239	3.1	2.4	15.5	11.3	16.1	11.7	22.7	16.7	1.6%	2.2%	
DERMAPHARM	59.70	EUR	3,214	4.1	3.8	15.6	13.9	19.5	17.1	24.6	21.8	2.1%	2.3%	č
ICON	210.35	USD	11,101	3.3	3.0	18.9	16.8	21.6	19.0	26.5	23.5	0.0%	0.0%	
JUBILANT LIFE SCIENCES	975.65	INR	155,403	1.7	1.5	7.8	6.8	10.3	8.9	13.4	11.8	0.5%	0.6%	
LABORATORIOS FARM. R	43.30	EUR	2,399	4.9	4.1	24.1	18.1	29.3	21.1	33.1	25.1	0.7%	1.0%	μ Έ
LANXESS	63.86	EUR	5,514	1.1	1.0	7.2	6.7	13.7	12.2	16.7	14.3	1.7%	1.9%	Ċ
PROBI	468.00	SEK	5,332	6.7	6.0	23.4	20.7	34.6	29.2	45.2	38.7	0.5%	0.5%	
RECIPHARM	222.00	SEK	22,389	2.6	2.4	13.6	12.1	27.0	22.4	31.5	25.2	0.9%	1.1%	(\mathbf{G})
SIEGFRIED	618.00	CHF	2,566	2.9	2.6	16.3	14.1	24.4	20.6	27.7	23.8	0.5%	0.5%	\sim
STRIDES PHARMA SCIEN	908.45	INR	81,429	2.4	2.0	10.9	9.0	15.4	12.5	19.1	14.5	0.6%	0.7%	5
Median				3.0	2.5	15.6	13.0	20.6	18.0	25.6	22.7	0.6%	0.9%	- 2
Source: Intermonte SIM 6			·	nies, FactSe	et consens	us estimates	for peer gro	pup						esea
		20					2022							Ľ

FINE FOODS - Estimates Comparison with Consensus

		2021			2022	
(Eu mn)	Intermonte	Consensus	%diff	Intermonte	Consensus	%diff
Revenues	215.9	215.6	0.1%	237.3	243.0	-2.3%
Ebitda	30.3	31.1	-2.6%	35.2	36.4	-3.3%
Net Profit	13.2	14.4	-8.4%	15.8	18.2	-13.2%
EPS	0.562	0.611	-8.0%	0.674	0.773	-12.7%
Net Debt	36.2	46.8	-22.7%	49.6	59.8	-17.0%

Source: Intermonte SIM estimates and Factset consensus estimates

DETAILS ON STOCKS RECOMMENDATION

Stock NAME	FINE FOODS		
Current Recomm:	OUTPERFORM	Previous Recomm:	OUTPERFORM
Current Target (Eu):	14.10	Previous Target (Eu):	13.00
Current Price (Eu):	10.75	Previous Price (Eu):	10.40
Date of report:	19/01/2021	Date of last report:	02/10/2020

DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte

panes wincord automicisation from interminitemonie. This report is directed exclusively at market professional and other institutional investors (institutions) and is not for distribution to person other than "institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution. The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor

should it be construed as a solicitation to buy or sell securities.

should tabe construed as a solicitation to buy or sell securities. This disclormer is constantly updated on Intermonte's website www.intermonte.it under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the <u>PERFORMANCE</u> web page. Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LL under SEC 156-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) disc certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report. The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokenge activities. Intermonte's intermon proceedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made. The analyst responsible for the report is _{and} a) a resident of US; b) an associated person of a US. broker-dealer; c) supervised by a supervisory principal of a US. broker-dealer. This Research Report is distributed in the US. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 10022.

GUIDE TO FUNDAMENTAL RESEARCH

- UIDE TO FUNDAMENTAL RESEARCH e main methods used to evoluate financial instruments and set a target price for 12 months after the investment recommendation are as follows: Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM) Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price /sales. Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value embedded portfolio value are used for the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB) value and
- Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 2.5% and a risk premium of 5.0% are being used.

Frequency of research: quarterly. Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important . wsflow

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published

Explanation of our ratings system:

Explanation of our rainings system: BUY: stock expected to outperform the market by over 25% over a 12 month period; OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period; NEUTRAL: stock performance expected at between +10% and - 10% compared to the market over a 12 month period; UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period; SELL: stock expected to underperform the market by between -10% and -25% over a 12 month period. Prices: The prices reported in the research refer to the price at the close of the previous day of trading

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Construction in trading in the construction of the construction of

BUY:	10.57 %
OUTPERFORM:	50.41 %
NEUTRAL:	34.95 %
UNDERPERFORM	04.07 %
SELL -	00.00.97

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (49 in total) is as follows:

BUY:	18.37 %
OUTPERFORM:	55.10 %
NEUTRAL:	26.53 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

CONFLICT OF INTEREST

ossible conflicts of interest Intermonte SIM states that:

Information to address to possible contracts of interest international and stores inductions in a line monte start store in the address to possible contracts of interest international international internations in the start store in the address international international international international international internations in the international internation internation international interna

Within the last year, Intermonte SIM managed or co-manageing or is co-managing on institutional Offering and/or managed or co-manageing or is co-managing on offering with firm commitment underwriting of the securities of the following Companies: BPER, IEG and lervolino Entertainment

underwining of the securities of the totowing Companies: BHz, IEJs and lervolino Entertainment. Intermonte SIM has provided in the tast 12 months / provides / may provide investment banking services to the following companies: Abitare In, Aedes, Aeroporto di Bologna, Alkemy, Azimut, Banca Ißis, Cellularline, Creval, ePrice, Falck Renewables, Guala Closures, H-Farm, IEG, lervolino Entertainment, Mittel, Nova Re, Retelit, Saes Getters, Somec, Tesmec, TXT, UBI Banca, and WIIT. Intermonte SIM is Specialist and/or Corporate Broker and/or Sporsor and/or Broker in charge of the share buy back activity of the following Companies: Abitare In, Aedes, Alkemy, Ambienthesis, Aquafi, Avio, Banca Ißis, Banca Sistema, Be, Catolica, CFT, Cellularline, Credito Valtellinese, Cyberoo, Cydgate, DeA Capital, ELEn, Eles, Elica, Emak, Esprinet, Falck Renewables, Fimit - Fondo Alpha, Fine Foods, Gefran, Go Internet, Gpi, Gruppo Fos, Guala, IEG, Iervolino Entertainment, IndelB, Industrial Stars Of Italy 3, Luve, Notorious, Relatech, Reno de Medici, Reply, Relefit, Saes Getters, Servizi Italia, Sesa, Seri Industrial, Somec, Tinesto, Temeor, Tandu MIIT. Intermonte SIM has a contractual commitment to act as liquidity provider on behall of thrid parties for the following companies: Banca Sistema, Restart, and Unieuro.

Intermente SIM has a contractual commitment to act as liquidity provider on behalf of third parties to the following comparies: Banca Sistema, Restart, and Unieuro. Intermente SIM performes as a market market for the following comparies: 2A, Anima, Altantia, Autogill, Adiunu Hodding, BANI, Banca Generati, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco, FCA, FIMB, Generati, Italgas, Iren. Interas Sanpaolo, Leonardo, Mediobanco, Moncler, Mediaset, PrietilikaC, Prysmian, Poster, Ferrati, Saipem, Snam, STM, Tenaris, Telecom Italia, Telecom Italia, San, Sun, UBI, Unicreatil, Unipol, Unipodiai. Intermonte SIM is a member of the CBOE Europe Equilities Liquidity Provider Program for the following financial Instruments: A2A, Atlantia, ATSM, Autogill, Azinut Hodding, Banca Generali, Banca Generali, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Carona Mediolanum, Banco BPM, Baca Monte del Paschi di Siena, Bca Pop Emilia Romagna, Banca Pop Sondio, Buzzi Unicem, Buzi Unicem, Mediaset, Mediobanca, Pipelli & C., Postel Italiana, Fenzi Buzo, Buzi, Casti Unice, Statuato Buzi, Casti Unicem, Hauzi Unicem, Buzi Unicem,

Through its Websim Division, Intermonte SIM carries out marketing / communication activities on behalf of the following equity crowdfunding 200Crowd, BacktoWork24, Crowdfundme, Opstart and the following issuers: Banca IMI, BNP Paribas, Credit Suisse, Exane, Leonteq, Unicredit, Vontobel, Wisdomtree.

Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers

Emittente	%	Long/Short
COGEME SET SPA	1.6	SHORT
IKF	0.57	SHORT
LIFE CARE CAPITAL	0.59	LONG
OLIDATA	0.74	SHORT

© Copyright 2020 by Intermonte SIM - All rights reserved

© Copyright 2020 by Intermonte SIM - All rights reserved It is a violation of national and intermational copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copyr this e-mail without the explicit written consent of Intermonte SIM. INTERMONTE will take legal action against anybody transmitting/publishing its Research product and deserves to be adequately paid. Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE is research product.

INTERMONTE SIM is MIRD compliant - for our Best Execution Policy please check our Website MIRD Further information is available